cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Dr. dr. Puspa Wardhani, SpPK
Contact Email
admin@indonesianjournalofclinicalpathology.org
Phone
+6285733220600
Journal Mail Official
majalah.jicp@yahoo.com
Editorial Address
Laboratorium Patologi Klinik RSUD Dr. Soetomo Jl. Mayjend. Prof. Dr. Moestopo 6-8 Surabaya
Location
Kota adm. jakarta selatan,
Dki jakarta
INDONESIA
Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML)
Published by Perhimpunan Dokter Spesialis Patologi Klinik Indonesia
ISSN : 08544263     EISSN : 24774685     DOI : https://dx.doi.org/10.24293
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience
Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) is a journal published by “Association of Clinical Pathologist” professional association. This journal displays articles in the Clinical Pathology and Medical Laboratory scope. Clinical Pathology has a couple of subdivisions, namely: Clinical Chemistry, Hematology, Immunology and Serology, Microbiology and Infectious Disease, Hepatology, Cardiovascular, Endocrinology, Blood Transfusion, Nephrology, and Molecular Biology. Scientific articles of these topics, mainly emphasize on the laboratory examinations, pathophysiology, and pathogenesis in a disease.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 21 Documents
 1   2   3 
Search results for , issue "Vol. 28 No. 2 (2022)" : 21 Documents clear
Immunogenicity Assessment on Clinical Trials of SARS-CoV-2 Vaccines Munawaroh Fitriah; Jusak Nugraha
INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY Vol. 28 No. 2 (2022)
Publisher : Indonesian Association of Clinical Pathologist and Medical laboratory

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24293/ijcpml.v28i2.1975

Abstract

Various strategies for dealing with COVID-19 have been carried out since the WHO declared COVID-19 as an international health emergency. One of the preventive strategies is the development of vaccines. Various vaccines have been developed worldwide. As of April 13, 2021, there were 184 vaccine candidates in the pre-clinical phase and 16 vaccine candidates currently in phase III clinical trials using several platforms, such as inactivated viruses, vector viruses, and protein subunits, and mRNA. Clinical trials of the SARS-CoV-2 vaccine include a screening test consisting of thorough physical examination and laboratory tests. The safety of clinical trials is evaluated based on laboratory test results referring to the standard toxicity grading scale. Immunogenicity assessment at the stage of clinical trials of vaccines includes assessment of humoral and cellular immunogenicity. The humoral immunogenicity test measures the ability of antibodies to neutralize the virus with the live virus neutralization test, Pseudo Virus Neutralization Test (pVNT), and Surrogate Virus Neutralization Test (sVNT) method. The cellular immunogenicity response aims to assess the immune response that leads to the Th1-cell phenotype. The COVID-19 vaccine under development is expected to trigger a helper 1 (Th1) cell response. Th1-producing Interferon-g (IFNg) is formed during acute viral infection, and Th1-type immune response correlates with milder disease. This is one of the considerations in vaccination. Th1-cell phenotype as part of cellular immunogenicity can be evaluated with ELISPOT, interferon-gamma release assay, and flow cytometry using blood samples that have been cultured with the administration of specific SARS-CoV-2 peptides. This literature review aims to study various immunogenicity assessments in the laboratory for clinical trials of COVID-19 vaccines.

Page 3 of 3 | Total Record : 21

 1   2   3 

Filter by Year

2022 2022


Reset
Filter By Issues
All Issue Vol. 32 No. 1 (2025) Vol. 31 No. 3 (2025) Vol. 31 No. 2 (2025) Vol. 31 No. 1 (2024) Vol. 30 No. 3 (2024) Vol. 30 No. 2 (2024) Vol. 30 No. 1 (2023) Vol. 29 No. 3 (2023) Vol. 29 No. 2 (2023) Vol. 29 No. 1 (2022) Vol 29, No 1 (2022) Vol 28, No 3 (2022) Vol. 28 No. 3 (2022) Vol. 28 No. 2 (2022) Vol 28, No 2 (2022) Vol. 28 No. 1 (2021) Vol 28, No 1 (2021) Vol 27, No 3 (2021) Vol. 27 No. 3 (2021) Vol. 27 No. 2 (2021) Vol 27, No 2 (2021) Vol. 27 No. 1 (2020) Vol 27, No 1 (2020) Vol. 26 No. 3 (2020) Vol 26, No 3 (2020) Vol 26, No 2 (2020) Vol. 26 No. 2 (2020) Vol 26, No 1 (2019) Vol. 26 No. 1 (2019) Vol. 25 No. 3 (2019) Vol 25, No 3 (2019) Vol. 25 No. 2 (2019) Vol 25, No 2 (2019) Vol 25, No 1 (2018) Vol. 25 No. 1 (2018) Vol 24, No 3 (2018) Vol. 24 No. 3 (2018) Vol. 24 No. 2 (2018) Vol 24, No 2 (2018) Vol. 24 No. 1 (2017) Vol 24, No 1 (2017) Vol 23, No 3 (2017) Vol. 23 No. 3 (2017) Vol 23, No 2 (2017) Vol. 23 No. 2 (2017) Vol 23, No 1 (2016) Vol 22, No 3 (2016) Vol 22, No 2 (2016) Vol 22, No 1 (2015) Vol 21, No 3 (2015) Vol 21, No 2 (2015) Vol 21, No 1 (2014) Vol 20, No 3 (2014) Vol 20, No 2 (2014) Vol 20, No 1 (2013) Vol 19, No 3 (2013) Vol 19, No 2 (2013) Vol. 19 No. 1 (2012) Vol 19, No 1 (2012) Vol 18, No 3 (2012) Vol. 18 No. 3 (2012) Vol 18, No 2 (2012) Vol 18, No 1 (2011) Vol. 18 No. 1 (2011) Vol 17, No 3 (2011) Vol 17, No 2 (2011) Vol 17, No 1 (2010) Vol 16, No 3 (2010) Vol 16, No 2 (2010) Vol 16, No 1 (2009) Vol 15, No 3 (2009) Vol 15, No 2 (2009) Vol 15, No 1 (2008) Vol 14, No 3 (2008) Vol 14, No 2 (2008) Vol 14, No 1 (2007) Vol 13, No 3 (2007) Vol 13, No 2 (2007) Vol 13, No 1 (2006) Vol 12, No 3 (2006) Vol 12, No 2 (2005) Vol 12, No 1 (2005) More Issue